Sofgen Pharma Statistics
Total Valuation
Sofgen Pharma has a market cap or net worth of 256.00 million. The enterprise value is 531.51 million.
| Market Cap | 256.00M |
| Enterprise Value | 531.51M |
Important Dates
The next estimated earnings date is Friday, May 15, 2026.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Sofgen Pharma has 2.33 billion shares outstanding.
| Current Share Class | 2.33B |
| Shares Outstanding | 2.33B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.06% |
| Owned by Insiders (%) | 2.80% |
| Owned by Institutions (%) | 6.94% |
| Float | 2.24B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.68 |
| PB Ratio | -4.91 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 3.71 |
| P/OCF Ratio | 2.89 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.78 |
| EV / Sales | 1.42 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 7.70 |
Financial Position
The company has a current ratio of 0.52
| Current Ratio | 0.52 |
| Quick Ratio | 0.29 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | 4.44 |
| Interest Coverage | -0.67 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -4.03% |
| Return on Invested Capital (ROIC) | -10.98% |
| Return on Capital Employed (ROCE) | 673.06% |
| Weighted Average Cost of Capital (WACC) | 169.96% |
| Revenue Per Employee | 83,102 |
| Profits Per Employee | -15,185 |
| Employee Count | 5,000 |
| Asset Turnover | 0.85 |
| Inventory Turnover | 2.04 |
Taxes
| Income Tax | -16.29M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.52% in the last 52 weeks. The beta is 64.78, so Sofgen Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 64.78 |
| 52-Week Price Change | -92.52% |
| 50-Day Moving Average | 0.70 |
| 200-Day Moving Average | 1.39 |
| Relative Strength Index (RSI) | 47.55 |
| Average Volume (20 Days) | 1,069 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 23.18 |
Income Statement
In the last 12 months, Sofgen Pharma had revenue of 373.80 million and -68.30 million in losses. Loss per share was -0.68.
| Revenue | 373.80M |
| Gross Profit | 191.48M |
| Operating Income | -28.48M |
| Pretax Income | -84.59M |
| Net Income | -68.30M |
| EBITDA | -19.13M |
| EBIT | -28.48M |
| Loss Per Share | -0.68 |
Balance Sheet
The company has 30.32 million in cash and 306.77 million in debt, with a net cash position of -276.46 million or -0.12 per share.
| Cash & Cash Equivalents | 30.32M |
| Total Debt | 306.77M |
| Net Cash | -276.46M |
| Net Cash Per Share | -0.12 |
| Equity (Book Value) | -52.09M |
| Book Value Per Share | -0.45 |
| Working Capital | -199.18M |
Cash Flow
In the last 12 months, operating cash flow was 88.43 million and capital expenditures -19.38 million, giving a free cash flow of 69.05 million.
| Operating Cash Flow | 88.43M |
| Capital Expenditures | -19.38M |
| Depreciation & Amortization | 9.35M |
| Net Borrowing | -54.64M |
| Free Cash Flow | 69.05M |
| FCF Per Share | 0.03 |
Margins
Gross margin is 51.23%, with operating and profit margins of -7.62% and -18.27%.
| Gross Margin | 51.23% |
| Operating Margin | -7.62% |
| Pretax Margin | -22.63% |
| Profit Margin | -18.27% |
| EBITDA Margin | -5.12% |
| EBIT Margin | -7.62% |
| FCF Margin | 18.47% |
Dividends & Yields
Sofgen Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.83% |
| Shareholder Yield | 0.83% |
| Earnings Yield | -26.68% |
| FCF Yield | 26.97% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sofgen Pharma has an Altman Z-Score of -0.93 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.93 |
| Piotroski F-Score | 3 |